Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patent Regulation Drops Deference To ANDA, 505(b)(2) Sponsors

Executive Summary

FDA's final rule implementing provisions of Medicare Modernization Act ‘will fuel litigation,’ attorney predicts.

You may also be interested in...

FDA ‘Monster’ Patent Reg: Brands, Generics Each Want More Options To Pick Fights

PhRMA is concerned about the agency giving deference to generic sponsors in patent use code disputes, while GPhA wants a mechanism to challenge refuse-to-receive letters.

FDA’s ‘Monster’ Proposed Rule Targets Patent Use Codes, Paragraph IV Certification

Industry has 90 days to comment on FDA’s current handling of generic challenges to brand protections.

Celebrex Generic Exclusivity Suit Could Have Broad Financial, Regulatory Reach

Appeals court says FDA violated Hatch-Waxman by awarding 180-day exclusivity solely to Teva based on reissued patent; celecoxib generics are already marketed but could step out from Pfizer-authorized status.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts